Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bradanicline - Attenua

Drug Profile

Bradanicline - Attenua

Alternative Names: ATA 101; TC-0569; TC-5619; TC-5619-238

Latest Information Update: 21 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targacept
  • Developer Attenua; Targacept
  • Class Amides; Azabicyclo compounds; Benzofurans; Nootropics; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cough
  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders

Most Recent Events

  • 05 Nov 2018 Phase-II clinical trials in Cough in USA (PO)
  • 11 Sep 2017 Attenua plans a phase II proof of concept trial for Cough in November 2018 (PO) (NCT03622216)
  • 11 Sep 2017 Preclinical trials in Cough in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top